Jane de Lartigue, PhD


Emerging Antiemetics Offer More Complete Control of Debilitating CINV

June 24, 2016

The new generation of drugs that has emerged as part of antiemetic cocktails has demonstrated greater success in preventing and controlling chemotherapy-induced nausea and vomiting (CINV), but the symptoms—particularly nausea—still present significant obstacles in anticancer therapy, and the ultimate goal of prevention in all patients has yet to be attained.

Update on BRCA1/2: Technical and Policy Questions Arise as Testing Options Expand

January 02, 2015

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing. In the past 18 months, the floodgates for testing options have opened, as companies seek to enter the diagnostic market in the wake of the US Supreme Court's June 2013 ruling that "naturally occurring" human genes are a "product of nature" and cannot be patented, breaking Myriad Genetics' monopoly on BRCA1/2 gene testing.